Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT03275311
Recruiting Observational

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

NCT03275311 · tracked via the Priya Life Science France tracker
Sponsor
UNICANCER
Phase
Observational
Started
2014-07
Last updated
2026-05-27

Condition(s) studied

Metastatic Breast Cancer

Study summary

The Epidemiological Strategy and Medical Economic (ESME) Breast cancer Database is a multicenter real life database using a retrospective data collection process across 18 French comprehensive cancer centers (FCCC) spread over 20 sites. This database compiles data from patient's electronic medical records (EMR).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria : * 18 years old patient * Patient receiving chemotherapy, targeted therapy, immunotherapy, radiation therapy and hormonotherapy in a French Comprehensive Cancer Center. Exclusion criteria : None

Primary outcome measure(s)

  • Describe the evolution of therapeutic care — baseline
    Patient characteristics, tumor characteristics and treatment patterns

Trial sites (20)

FacilityCityRegionStatus
Institut de Cancérologie de l'Ouest - Paul Papin Angers France Recruiting
Institut Bergonié Bordeaux France Recruiting
Centre François Baclesse Caen France Recruiting
Centre Jean Perrin Clermont-Ferrand France Recruiting
Centre Georges-François Leclerc Dijon France Recruiting
Centre Oscar Lambret Lille France Recruiting
Centre Léon Bérard Lyon France Recruiting
Institut Paoli-Calmettes Marseille France Recruiting
Institut régional du Cancer Montpellier / Val d'Aurelle Montpellier France Recruiting
Institut de Cancérologie de Lorraine Nancy France Recruiting
Institut de cancérologie de l'Ouest - René Gauducheau Nantes France Recruiting
Centre Antoine Lacassagne Nice France Recruiting
Institut Curie Paris France Recruiting
Institut Jean Godinot Reims France Recruiting
Centre Eugène Marquis Rennes France Recruiting
Centre Henri Becquerel Rouen France Recruiting
Institut Curie - Hôpital René Huguenin Saint-Cloud France Recruiting
Centre Paul Strauss Strasbourg France Recruiting
Institut Claudius Regaud Toulouse France Recruiting
Institut Gustave Roussy Villejuif France Recruiting

More UNICANCER trials in France

A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer Recruiting
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer Active, not recruiting
QUALIOR Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program Active, not recruiting
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases Active, not recruiting
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. Recruiting

Other trials for the same condition

Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases Active, not recruiting
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Recruiting
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR) Recruiting
PERCIST Evaluation of Trastuzumab Deruxtecan in the Treatment of HER2 Low Breast Cancer Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03275311 on ClinicalTrials.gov ↗ ← All trials in France